Insight on why Johnson & Johnson exceeded his expectations, with Jeff Jonas, GAMCO analyst/portfolio manager, who adds that Johnson & Johnson's pharma business will start to accelerate with new launches and bring leverage to the company's bottom line.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT